GlassScriptPhysician profile
Ronald A Ford
NPI 1285602474
$5,834.73
in general payments reported to CMS, 2019-2025
30 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $701 · 2021: $936 · 2022: $1,197 · 2023: $1,128 · 2024: $521 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,065.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $887.41 | 2019-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $653.17 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $644.98 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $549.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $502.37 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $420.51 | 2019-2023 | Verquvo, Belsomra, Janumet |
| Lilly USA, LLC | $337.26 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $326.65 | 2020-2025 | |
| Abbvie INC. | $197.78 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $165.50 | 2021-2024 | |
| Dexcom, INC. | $144.27 | 2022-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $127.68 | 2019-2025 | Shingrix, Arexvy |
| Exact Sciences Corporation | $97.05 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $92.56 | 2021-2024 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $91.90 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $74.14 | 2019-2022 | |
| Astellas Pharma US INC | $65.10 | 2019-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $63.16 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $61.39 | 2019-2022 | |
| Allergan, INC. | $57.12 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $49.68 | 2019-2023 | |
| Abbott Laboratories | $47.85 | 2024-2025 | Freestyle Libre 3, Freestyle Libre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.66 | 2021-2022 | |
| Daiichi Sankyo INC. | $22.31 | 2023 | Injectafer |
| Mylan Specialty L.P. | $21.42 | 2023 | Yupelri |
| Inari Medical, INC. | $21.19 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Sunovion Pharmaceuticals INC. | $20.42 | 2019 | |
| Idorsia Pharmaceuticals US INC | $18.78 | 2023 | Quviviq |
| Tolmar, INC. | $18.02 | 2025 | Jatenzo |
| Biohaven Pharmaceuticals, INC. | $12.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.